Precision oncology: separating the wheat from the chaff

被引：31
|
作者：
Remon, Jordi [1 ]
Dienstmann, Rodrigo [2 ]
机构：
[1] HM Delfos, Ctr Integral Oncol Clara Campal Barcelona, Med Oncol Dept, Barcelona, Spain
[2] Hosp Valle De Hebron, Oncol Data Sci ODysSey Grp, Barcelona, Spain
来源：
ESMO OPEN | 2018年 / 3卷 / 06期
关键词：
CELL LUNG-CANCER; METASTATIC BREAST-CANCER; OPEN-LABEL; MOLECULAR CHARACTERIZATION; ANTICANCER DRUGS; TARGETED THERAPY; FDA APPROVAL; SOLID TUMORS; PHASE-II; MEDICINE;
D O I：
10.1136/esmoopen-2018-000446
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Precision oncology based on next-generation sequencing (NGS) test is growing in daily clinical practice. However, the real impact of this strategy in patients' outcome on a large scale remains uncertain. In this review, we summarise existing literature on this topic, limitations for broad NGS implementation, bottlenecks in genomic variant interpretation and the role of molecular tumour boards.
引用
收藏
页数：7
相关论文
共 50 条
  • [31] Progress in precision therapy in pediatric oncology
    O'Donohue, Tara
    Sait, Sameer Farouk
    Bender, Julia Glade
    CURRENT OPINION IN PEDIATRICS, 2023, 35 (01) : 41 - 47
  • [32] Precision oncology: a clinical and patient perspective
    Lassen, Ulrik N.
    Makaroff, Lydia E.
    Stenzinger, Albrecht
    Italiano, Antoine
    Vassal, Gilles
    Garcia-Foncillas, Jesus
    Avouac, Bernard
    FUTURE ONCOLOGY, 2021, 17 (30) : 3995 - 4009
  • [33] From Cancer Genomics to Precision Oncology-Tissue's Still an Issue
    Cohen, Robert L.
    Settleman, Jeff
    CELL, 2014, 157 (07) : 1509 - 1514
  • [34] Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice
    Lin, Jianzhen
    Dong, Kun
    Bai, Yi
    Zhao, Songhui
    Dong, Yonghong
    Shi, Junping
    Shi, Weiwei
    Long, Junyu
    Yang, Xu
    Wang, Dongxu
    Yang, Xiaobo
    Zhao, Lin
    Hu, Ke
    Pan, Jie
    Sang, Xinting
    Wang, Kai
    Zhao, Haitao
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7 (18)
  • [35] Precision Oncology in Canada: Converting Vision to Reality with Lessons from International Programs
    Liu, Geoffrey
    Cheung, Winson Y.
    Feilotter, Harriet
    Manthorne, Jackie
    Stockley, Tracy
    Yeung, ManTek
    Renouf, Daniel J.
    CURRENT ONCOLOGY, 2022, 29 (10) : 7257 - 7271
  • [36] Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers
    Groisberg, Roman
    Hong, David S.
    Roszik, Jason
    Janku, Filip
    Tsimberidou, Apostolia M.
    Javle, Milind
    Meric-Bernstam, Funda
    Subbiah, Vivek
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (07) : 1595 - 1601
  • [37] Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
    Gouda, M. A.
    Subbiah, V.
    ESMO OPEN, 2023, 8 (02)
  • [38] Genomics driven precision oncology in advanced biliary tract cancer improves survival
    Kumar-Sinha, Chandan
    Vats, Pankaj
    Tran, Nguyen
    Robinson, Dan R.
    Gunchick, Valerie
    Wu, Yi-Mi
    Cao, Xuhong
    Ning, Yu
    Wang, Rui
    Rabban, Erica
    Bell, Janice
    Shankar, Sunita
    Mannan, Rahul
    Zhang, Yuping
    Zalupski, Mark M.
    Chinnaiyan, Arul M.
    Sahai, Vaibhav
    NEOPLASIA, 2023, 42
  • [39] Precision neuro-oncology: a pilot analysis of personalized treatment in recurrent glioma
    Lazaridis, Lazaros
    Schmidt, Teresa
    Oster, Christoph
    Blau, Tobias
    Pierscianek, Daniela
    Siveke, Jens T.
    Bauer, Sebastian
    Schildhaus, Hans-Ulrich
    Sure, Ulrich
    Keyvani, Kathy
    Kleinschnitz, Christoph
    Stuschke, Martin
    Herrmann, Ken
    Deuschl, Cornelius
    Scheffler, Bjorn
    Kebir, Sied
    Glas, Martin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3513 - 3526
  • [40] Precision oncology with selective RET inhibitor selpercatinib in RET-rearranged cancers
    Gouda, Mohamed A.
    Subbiah, Vivek
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15
12345